Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced receiving clinical trial approvals for its novel anti-microbial agent MRX-4, combined with contezolid (MRX-I), as a sequential treatment for diabetic foot infection in Israel, Bulgaria, Slovakia, Croatia, Poland, and Brazil.
In-House Developed Oxazolidinone Antibiotics
Both MRX-4 and contezolid are in-house developed new-generation oxazolidinone antibiotics. Contezolid was approved in China in June 2021 for the treatment of complex skin and soft tissue infections. MRX-4, also known as contezolid acefosamil, is the pro-drug version of contezolid (MRX-1), a potent oxazolidinone antibiotic effective against Gram-positive pathogens.
Global Clinical Trial Expansion
The MRX-4/contezolid combination, previously approved for use as a sequential treatment for infections caused by drug-resistant Gram-positive bacteria, has obtained clinical trials in the USA, China, France, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Spain, and Estonia. This global expansion of clinical trials underscores the potential impact of MicuRx Pharmaceuticals’ antibiotics in addressing the growing challenge of drug-resistant infections worldwide.-Fineline Info & Tech
